Public source

Reviewed 9 Jun 2026

Completeness Fair (39%)

aPromise

EXINI

aPROMISE is a software solution for quantitative analysis and standardized reporting of PSMA PET/CT images in prostate cancer. It automatically detects, segments, and quantifies lesions and disease burden, supporting image interpretation.

No papers to support — we monitor for new evidence.

Key features

PSMA PET/CT image

General Information

Product name

aPromise

Company

Modality

CT, PET

Main task

Detection, Quantification

Subspeciality

Abdomen

Disease targeted

Prostate cancer, metastases

Regulatory Information

CE Certification

Pathway:

MDR

Class:

Class IIa

Not verified by Health AI Register

FDA Certification

Pathway:

510(k) cleared

Class:

Class II

FDA Number:

Verified by Health AI Register

Other certifications

Not specified

Evidence & Research

No research papers or evidence on file yet.

The registry monitors publications for new evidence.

Technical Specifications

Patient population age

Not specified

Input

PSMA PET/CT images

Input format

Not specified

Output

Not specified

Output format

Not specified

Integration

Not specified

Deployment

Not specified

Trigger for analysis

Not specified

Processing time

Not specified

Population

Not specified

Market Presence

On market since

Not specified

AI Platforms

Resellers

Not specified

Countries present

Not specified

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

Not specified

Based on

Not specified

Source: Public | First published: Mar 31, 2026 | Last updated: Jun 9, 2026

aPromise - EXINI